AU2483499A - Pharmaceutical uses of optically pure (+)-bupropion - Google Patents

Pharmaceutical uses of optically pure (+)-bupropion Download PDF

Info

Publication number
AU2483499A
AU2483499A AU24834/99A AU2483499A AU2483499A AU 2483499 A AU2483499 A AU 2483499A AU 24834/99 A AU24834/99 A AU 24834/99A AU 2483499 A AU2483499 A AU 2483499A AU 2483499 A AU2483499 A AU 2483499A
Authority
AU
Australia
Prior art keywords
bupropion
administered
amount
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24834/99A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22110794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2483499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2483499A publication Critical patent/AU2483499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
AU24834/99A 1998-01-29 1999-01-28 Pharmaceutical uses of optically pure (+)-bupropion Abandoned AU2483499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7295598P 1998-01-29 1998-01-29
US60072955 1998-01-29
PCT/US1999/001952 WO1999038502A1 (en) 1998-01-29 1999-01-28 Pharmaceutical uses of optically pure (+)-bupropion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003203883A Division AU2003203883A1 (en) 1998-01-29 2003-04-24 Pharmaceutical uses of optically pure(+) - Bupropion

Publications (1)

Publication Number Publication Date
AU2483499A true AU2483499A (en) 1999-08-16

Family

ID=22110794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24834/99A Abandoned AU2483499A (en) 1998-01-29 1999-01-28 Pharmaceutical uses of optically pure (+)-bupropion

Country Status (5)

Country Link
EP (1) EP1051166A1 (ja)
JP (1) JP2002501890A (ja)
AU (1) AU2483499A (ja)
CA (1) CA2318960A1 (ja)
WO (1) WO1999038502A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) * 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US9732031B2 (en) 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
AU2019223187B2 (en) * 2018-02-23 2022-07-28 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) * 2018-09-20 2022-08-11 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) 2018-09-20 2022-09-06 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20200093760A1 (en) 2018-09-20 2020-03-26 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) 2018-09-20 2022-05-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
EP4031121A4 (en) * 2019-09-20 2022-11-30 Axsome Therapeutics, Inc. DOSAGE FORMS AND METHODS FOR FORMING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones

Also Published As

Publication number Publication date
EP1051166A1 (en) 2000-11-15
JP2002501890A (ja) 2002-01-22
WO1999038502A1 (en) 1999-08-05
CA2318960A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
EP1259243B1 (en) Bupropion metabolites and methods of their synthesis and use
US20030130355A1 (en) Therapeutic agents
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2013256526A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
CA2138998A1 (en) Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
EP0687472A2 (en) Potentiation of drug response by a serotonin 1A receptor antagonist
JP2001503737A (ja) 糖尿病の発生を防止するためのシブトラミン類似体の利用
WO1999038503A1 (en) Pharmacological uses of optically pure (+)-bupropion
AU2483499A (en) Pharmaceutical uses of optically pure (+)-bupropion
CA2139000A1 (en) Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
EP0759299A1 (en) Potentiation of serotonin response
EP0612242B1 (en) Use of the pure s(+) isomer of fluoxetine for the preparation of a medicament against migraine headache
AU2349899A (en) Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
SK3272001A3 (en) A new composition
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
AU6172699A (en) Methods and compositions utilizing pure S()isomer fluoxetine

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted